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Detection of MCM5 as a novel non-invasive
aid for the diagnosis of endometrial and
ovarian tumours
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Abstract
Background: MCM5 is a protein involved in DNA replication, facilitating cell proliferation. In normal epithelium MCM5
expression is restricted to the cells in the basal proliferative compartments, however in the presence of a tumour
MCM5 positive cells are present at the surface epithelium and are shed into bodily fluids. The aim of this study was to
determine the sensitivity of MCM5 as a biomarker for the detection of endometrial and ovarian cancer.
Methods: Patients with known ovarian or endometrial cancers, or known benign gynaecological conditions, were
enrolled. Informed consent was obtained prior to the collection of full void urine, and either a vaginal tampon (worn
for 6–8 h), or a vaginal swab. Vaginal secretions were extracted from the tampon or swab, centrifuged and lysed. Urine
samples were centrifuged and lysed. MCM5 levels were determined by MCM5-ELISA (Arquer Diagnostics Ltd).
Results: 125 patients completed the study protocol, 41 patients had endometrial cancer, 26 ovarian cancer, and 58
benign controls. All patients provided a urine sample and either a tampon or vaginal swab sample. Urine MCM5 levels
were higher in cancer patients than controls (p < 0.0001), there was no significant difference in levels between tampon
samples or vaginal swab samples in cancer patients when compared to controls.
Performance of MCM5 to discriminate cancer from benign disease was high with an area under the ROC curve of 0.83
for endometrial cancer and 0.68 for ovarian cancer. Using a cut off of 12 pg/mL, overall sensitivity for endometrial
cancer was 87.8, and 61.5% for ovarian cancer with a specificity of 75.9%.
Conclusions: MCM5 is a novel sensitive and specific biomarker for the detection of ovarian and endometrial tumours
in urine samples, which is likely to have clinical utility as a diagnostic aid.
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Background
Ovarian and endometrial cancers, the cancers of the
upper female genital tract, share many similarities [1, 2].
Combined, they represent a major disease burden with
over 16,000 cases diagnosed each year in the UK. Both
actually represent a collection of different histological
subtypes, some of these subtypes being common to both
ovarian and endometrial cancer, and both organs are in
direct continuity, via the fallopian tubes and the cervix,
with the lower genital tract.
To date, screening and early diagnosis of upper genital
tract cancers has been challenging. Although many
patients with endometrial cancer present with post
menopausal bleeding this is by no means universal
whilst ovarian cancer is notorious for late presentation,
in part because of a lack of red flag symptoms. Screening
for ovarian cancer, in the form of CA125 and transvagi-
nal ultrasound has not been demonstrated to improve
clinical outcome [3]. Furthermore diagnostic tests for
patients suspected of having endometrial and ovarian
disease lack specificity, leading to unnecessary surgery,
and are invasive which patients find unacceptable.
There is therefore a significant unmet need to generate
better tests that can be used, alone or in combination, in
either a screening or a diagnostic setting.
Spontaneous shedding of cancer cells from upper geni-
tal tract gynaecological tumours, which migrate through
the cervix and are secreted vaginally, may prove a critical
phenomenon to aid the development of new tests.
In endometrial cancer the presence of tumour cells in
the lower genital tract has been shown through a num-
ber of methods. Incidental findings of Pap smears (for
cervical cancer screening) found that 20% of endometrial
cancer patients have endometrial cancer cells present in
the cytology of the Pap smear [4]. There have also been
a number of studies which have demonstrated the detec-
tion of molecular markers in cervico-vaginal secretions
of endometrial cancer patients, further strengthening the
hypothesis that cancer cells are shed and secreted vagi-
nally [5, 6].
Testing for the presence of cells is labour intensive
and includes a degree of subjectivity. Conversely, mo-
lecular markers are also relatively expensive and require
specialist equipment. The ideal test is one that can be
replicated easily and reliably in any suitable pathology
laboratory.
MCM5(mini chromosome maintenance 5) is a DNA
licensing factor involved in cell proliferation, and has
been previously established as an excellent biomarker in
a number of malignancies, including cervical, bladder
and prostate cancer [7–9]. MCM5 plays a critical role in
DNA replication (reviewed in [10]) and is expressed in
any cell capable of proliferation. Importantly, however,
expression is lost in terminally differentiated cells. In a
normal epithelial structure MCM5 positive, proliferating
cells are thus restricted to the basal ‘stem-cell’ compart-
ment, with cells at the epithelial surface being terminally
differentiated (and therefore MCM5 negative). Therefore
any cells lost into bodily fluids, such as urine, seminal
fluid or vaginal discharge should not express MCM5.
However, in the case of a malignancy whereby cell
growth is uncontrolled and there is an increase in the
immature-non-differentiated cells these cells can be
found at epithelial surfaces and therefore may be found
in bodily fluids. MCM5 can be measured using the
widely available technique of ELISA.
Our purpose was to determine whether MCM5 could
be detected in the urine and/or vaginal secretions from
patients with gynaecological cancers and if this could be
used to differentiate from patients with benign conditions.
Methods
Study population
Subjects and controls were enrolled into the study at
Saint Mary’s Hospital, Manchester, between March
2017–July 2019, ethical approval was obtained from
South Central- Oxford B Research Ethics Committee
(16/SC/0643) and informed consent obtained from all
patients prior to the collection of urine, tampon or swab
samples. For the cancer cohort all eligible patients with
a known or strong suspicion of ovarian or endometrial
cancer were enrolled, whilst for the benign cohort all
eligible patients with a known benign condition (namely
Endometriosis, Fibroids, Polycystic Ovary syndrome
(PCOS) and Post-menopausal bleeding (PMB)) were
enrolled. Patients were excluded if they were virgo
intacta, if they had a previous diagnosis of bladder or
renal cancer, if the patient had undergone any urological
instrumentation in the preceding two weeks or if the
patient was currently receiving chemotherapy or radio-
therapy. All patients were confirmed to have negative
cervical cytology within the previous three years and all
patients underwent cross sectional imaging to exclude
other malignancies including urothelial malignancies.
Patients were asked to provide two samples, a full void
urine sample and either a vaginal swab collected by the
research nurse, or a vaginal tampon worn 6–8 h prior to
their appointment.
Sample processing-urine
A minimum of 25 mL urine was collected from each
patient, urine was agitated to ensure a homogenous mix
and up to 50mL was transferred into a clean centrifuge
tube. Samples were centrifuged at room temperature at
1500 g for 5 min. Supernatant was discarded taking care
not to disturb the cell sediment pellet and tubes were
placed upside down to drain on absorbent paper. Cell
sediment pellets were resuspended in an appropriate
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volume of ADXLYSIS buffer (Arquer Diagnostics Ltd)
(10uL per mL of urine) and incubated at room temperature
for 1 h before being stored at less than -20 °C.
Sample processing-vaginal tampon
Patients were asked to wear a commercially available
cardboard applicator vaginal tampon and instructed to
place the tampon in their vagina for 6–8 h prior to their
attendance at the clinic. The tampon was removed and
placed in a 50mL centrifuge tube and phosphate
buffered saline (PBS) added. The tampon was transferred
to a large syringe and compressed to release the PBS/
cells from the tampon. The PBS/cells from the tampon
were collected in a fresh 50ml centrifuge tube. Tubes
containing PBS/cells extracted from the syringe were
centrifuged at room temperature at 1500 g for 5 min.
Supernatant was discarded, taking care not to disturb
the cell sediment pellet. Tubes were placed upside
down on absorbent paper to drain and the cell sedi-
ment pellets were resuspended in 300 μL Lysis buffer
and incubated at room temperature for 1 h before
being stored at less than -20 °C.
Sample processing-vaginal swab
Vaginal swabs were collected by the research nurse,
briefly; a soft endocervical collection brush was inserted
3–5 cm into the vagina and rotated four times (two
towards the left and two towards the right). The swab
was then placed into 5 mL of PBS. The vaginal swab was
removed from the tube and the PBS was centrifuged at
room temperature at 1500 g for 5 min. Supernatant was
discarded, taking care not to disturb the cell sediment
pellet. Tubes were placed upside down to drain on absorb-
ent paper and the cell sediment pellets were resuspended
in 300 μL Lysis buffer and incubated at room temperature
for 1 h before being stored at less than -20 °C.
MCM5 ELISA
Patient lysates were tested with an MCM5 ELISA as
per manufacturer’s instructions (Arquer Diagnostics).
Briefly; 100 μL of lysate was added to each of 2 wells of
the MCM5 ELISA micro-titre plate (samples and con-
trols were run in duplicates) and incubated for 60 min
at room temperature on a plate shaker (700RPM).
Following incubation wells were washed 6 times with
350 μL of 1x wash buffer using an automated plate
washer. 100 μL of MCM5-HRP conjugated antibody
(Arquer Diagnostics Ltd., Sunderland UK) was added
to each well and incubated at room temperature for
30 min prior to being washed 6 times with 350 μL of
1x wash buffer as above. 100 μL of TMB was added to
each well and incubated for 30 min in the dark prior to
the addition of a stop solution (0.5 M H2SO4). Optical
density (OD) was measured at 450 nm and 630 nm
(reference wavelength). Concentrations of MCM5 were
calculated using a serial dilution standard curve of a
known recombinant MCM5 control (1.3 mg/ml) with a
negative control (Lysis Buffer).
Statistical analysis
The study was carried out and reported in line with the
20 recommendations set out in the STARD 2015 guid-
ance for diagnostic test reporting [11].
Data were analysed using MS Excel and GraphPad
Prism (v7.04). The chi square test was used to assess cat-
egorical variables and receiver operating characteristic
curves were generated to assess performance of the
assay. The cut-off point of 12 pg/mL was determined by
the manufacturer’s instructions as determined from
previous studies [7]. ROC curves were generated using
MCM5 level as a continuous variable and presence or
absence of malignancy as a discrete variable.
Using the methodology described by Pepe et al. [12] it
is possible to model the potential clinical utility of a
biomarker incorporating both the incidence and possible







In this equation, TPR is the true positive rate, FPR is
the false positive rate (1-specificity) and TPR/FPR de-
fines the actual performance of the test. p represents the
prevalence of the cancer and r is the cost benefit ratio
and the right side of the equation defines the
performance required. Where the actual performance is
greater than the performance required (i.e. where left
side of equation is greater than the right) then the test is
likely to have clinical utility.
Results
Clinical characteristics
Sixty-seven cancer patients were recruited and com-
pleted the study protocol, 41/67 with proven endomet-
rial cancer and 26/67 with confirmed ovarian cancer.
Cancer patients had a median age of 70 (IQR: 55–77)
(endometrium) and 63 (IQR 52–69) (ovary) which is
typical for these diseases, Table 1. There was good rep-
resentation of all subtypes, grade and stages of cancer
within the cohort with 29/41 (71%) endometrium and
8/26 (31%) ovarian being stage 1, Table 1.
Fifty-eight control patients were also recruited and
completed the study protocol. These were patients attend-
ing gynaecology clinics for benign disease. Median age
was younger than the cancer patients (49) (IQR 39–56)
and patients had a variety of benign conditions, Table 2,
but none developed cancer within 6months following
recruitment.
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A further 22 patients were approached but either
declined to participate or failed to complete the study
protocol. Specifically 3 patients stated they were unable,
or not prepared, to wear a tampon for the required eight
hours.
MCM5 levels in the urine sediment of cancer patients
compared to controls
MCM5 levels were tested in samples (urine sediment, plus
vaginal swab or tampon) from all 67 cancer patients and
all 58 control patients. Median levels were higher in the
urine samples from cancer patients (17.60 pg/mL) com-
pared to controls (2.81 pg/mL), p < 0.0001, Fig. 1a. Al-
though median levels of MCM5 were slightly higher in
the swab and tampon samples from cancer patients com-
pared to controls these were non significant, Fig. 1b and c.
Urine sediment MCM5 as a discriminator of both
endometrial and ovarian cancer
Comparing MCM5 levels in urine sediment samples
from patients with endometrial cancer with controls
showed a highly significant increase in cancer cases
(median 20.57 pg/mL for cancer and 2.81 pg/mL for
controls), Fig. 2. Using a pre defined cut off of 12 pg/mL
resulted in a correct classifier in 80/99 (80.1%) cases,
Table 3. Overall sensitivity for endometrial cancer was
87.8% and remained high for both low grade disease
(85.7, 95% CI: 57.2–98.2%) and low stage disease (86.2,
95% CI: 68.3–96.1%), Table 4.
Comparing MCM5 levels in urine sediment samples
from patients with ovarian cancer with controls showed
a highly significant increase in cancer cases (median
12.85 pg/mL for cancer and 2.81 pg/mL for controls),
Fig. 3. Using a cut off of 12 pg/mL resulted in a correct
Table 2 Patient Demographics of benign cohort at time of
recruitment
Characteristic N(%) or median
(interquartile range)
Benign cohort




Post menopausal bleeding 18 (31)
Ovarian Cyst 4 (7)
Polycystic ovaries 7 (12)
Infarcted fibroma 1 (2)
Mature Cystic Teratoma 2 (3)
Not recorded 3 (5)
Table 1 Patient Demographics of cancer cohort at time of recruitment
Characteristic N (%) or median (interquartile range)
Endometrial cancer cohort Ovarian cancer cohort
Age (year) 70 (57-77) 63 (52-69)
Histological subtype
Endometrioid 24 (59) 3 (12)
Serous 6 (15) 15 (58)
Clear cell 5 (12) 1 (4)
Squamous cell - 1 (4)
Carcinosarcoma 4 (10) -
Adenocarcinoma NOS - 1 (4)
Not recorded 2 (5) 2 (8)
Grade
Borderline - 3 (12)
G1 14 (34) 4 (15)
G2 10 (24) 3 (12)
G3 17 (41) 16 (62)
FIGO stage
I 29 (71) 8 (31)
II 4 (10) 4 (15)
III 7 (17) 10 (38)
IV 1 (2) 1 (4)
Not recorded - 3 (12)
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classifier in 60/84 (71.4%) cases, Table 5. Overall sensi-
tivity for ovarian cancer was 61.5% but interestingly was
higher for low grade disease (71.4, 95%CI: 29.0–96.3%)
and low stage disease (75, 95%CI: 34.9–96.8%). Two-
thirds of the borderline ovarian samples had levels greater
than 12 pg/mL classifying them as positive.
Specificity for the MCM5 test in this cohort was 75.9%
(95%CI: 62.8–86.1%). None of the benign conditions
tested showed an increase in MCM5 levels compared to
the remaining controls (data not shown).
Potential clinical utility for the MCM5 test
Overall performance of the MCM5 test was higher for
endometrial cancer with an area under the ROC curve
of 0.83 compared to 0.68 for ovarian cancer, Fig. 4, sug-
gesting a good performance for MCM5 as a biomarker,
at least for endometrial cancer. However clinical utility
of a biomarker is dependent upon not only performance
of the biomarker but also the incidence/prevalence of
the condition being tested, and the cost benefit ratio of
employing the assay.
Using the Pepe model (see methods) MCM5 actual
performance was therefore compared to the performance
required for two clinical settings, namely the asymptom-
atic screening population and a diagnostic testing popu-
lation (following referral for symptoms).
For the asymptomatic screening population age stan-
dardised incidence of disease was used for prevalence
(33/100,000 for endometrial and 40/100,000 for ovarian
[13]), whilst for the diagnostic testing population p = 3%
was used, given that this is the minimum threshold re-
quired for referral by NICE [14]. r was set at 0.1, the
value given for a scenario of 10 patients being subjected
to unnecessary tests for each cancer case diagnosed [12],
a value widely accepted in the literature [15].
As expected, performance required for a screening test
was higher (302.9 for endometrial and 249.9 for ovarian)
than for a diagnostic test (3.2 for endometrial and 3.2
Fig. 1 MCM5 level in Benign vs Cancer patients detected in (a)
Urine, (b) Vaginal Tampon, (c) Vaginal Swab
Fig. 2 MCM5 levels in urine sediment in Benign vs
Endometrial Cancer
Table 3 Contingency table for test performance for
endometrial cancer
Endometrial cancer
MCM5 result Positive Negative
Positive 36 14
Negative 5 44
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for ovarian). Actual performance of the MCM5 test
(3.6 for endometrial and 2.5 for ovarian) was there-
fore substantially lower than required for a screening
test but broadly equivalent to that needed for a diag-
nostic test, Table 6.
Discussion
Here we have shown that the DNA licensing factor
MCM5 can be detected in the urine sediment of patients
with gynaecological cancers at levels in excess of those
found in patients with benign gynaecological conditions.
Urine sediment testing was more successful than vaginal
tampon or vaginal swab testing and was more acceptable
to patients. Of particular interest was that the detection
of MCM5 was maintained, and possibly improved, in
patients with low stage and low grade disease, which is
encouraging for clinical use where detection of early
stage, low grade disease is critical.
Biomarkers have clinical utility in both the asymptom-
atic population as screening tests and as part of the
diagnostic pathway for patients with symptoms. Per-
formance accuracy requirements are different for these
two settings with asymptomatic screening in particular
requiring tests with extremely high specificities to avoid
over investigation [15]. Whilst the MCM5 test outlined
here does not, at this stage, appear to be associated with
the specificity required for a screening test it may have
an important role, alone, or in conjunction with other
tests, as part of the diagnostic process. Particularly, as it
is non-invasive, it may have an important role early in
the pathway as a “rule out” test to avoid unnecessary
further invasive testing in those who are at low risk of
harbouring disease.
To this end, whilst this is an early phase diagnostic
accuracy study it benefits from including benign
gynaecological conditions in the control arm as these
patients are often represented in a diagnostic clinic
and require differentiation from those who have can-
cer. However the numbers in the current study re-
main small and further studies including larger
numbers and replicating more closely the clinical set-
ting are justified. Specifically, future studies should
replicate the prevalence of cancer more accurately
than in the current dataset.
The MCM5 test has previously been shown to have
utility in bladder and prostate cancer [7, 8] and has been
shown to have signal in cervical intraepithelial neoplasia
and Barrets oesophagus. However this is the first time
that it has been shown to be of use in gynaecological
cancers. The MCM5 test is an easy-to-perform ELISA
test, compatible with general laboratory equipment
available in most hospital laboratories, and can provide
results within 3 h, without the need for a pathologist,
making it a potential low-cost alternative or adjunct to
cytology, which remains non standardised for gynaeco-
logical cancers, or other methodologies. It is likely that
the use of MCM5 as an adjunctive test will improve
sensitivity and, when combined with other tests in this
way, be associated with appropriate specificity.
It is perhaps not surprising that the MCM5 test
performed better as a test for endometrial cancer than
for ovarian cancer. Lesions in the endometrial cavity are
located closer to the vagina and cells shed from these
tumours are more likely to be detected in vaginal fluid
Table 4 Diagnostic performance of MCM5 urine test as a
biomarker by tumour type
Ovarian cancer
MCM5 result Positive Negative
Positive 16 14
Negative 10 44
Fig. 3 MCM5 levels in urine sediment in Benign vs Ovarian Cancer
Table 5 Contingency table for test performance for ovarian
cancer
Type of tumour(n) Sensitivity(%) Specificity (%)
(95%CI(%)) (95%CI(%))
Endometrial cancer (41) 87.8 (73.8-95.9) 75.9 (62.8-86.1)
Low grade(14) 85.7 (57.2-98.2) -
High Grade(27) 88.9 (70.8-97.7) -
Stage I (29) 86.2 (68.3-96.1) -
Stage II and above(12) 91.7 (61.5-99.8) -
Ovarian cancer(26) 61.5 (40.6-79.8) 75.9 (62.8-86.1)
Low Grade(7) 71.4 (29.0-96.3) -
High Grade(19) 57.9 (33.5-79.8) -
Stage I(8) 75.0 (34.9-96.8) -
Stage II and above(15) 53.3 (26.6-78.7) -
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or urine compared to tumours located higher in the
genital tract. However, it is now widely accepted that
many high grade serous cancers arise in the fallopian
tube rather than the ovary and thus the MCM5 test may
have use in at least some of these cancers. Utilising the
MCM5 test for this indication should not be ignored in
future studies.
The wearing of a tampon was unpopular with patients
and furthermore was associated with high readings in
the control patients with benign disease, which resulted
in the poor performance of MCM5 as a discriminator in
this settingThis may be related to the tampon causing
trauma to the vaginal mucosa, thus exposing basal cells
that normally express MCM5. Further studies should
therefore be limited to assessment of urine sediment but
it will be important to ensure that samples collected in
such studies do not follow instrumentation, or indeed
examination, of the lower genital tract.
Conclusions
Here we have demonstrated for the first time, that a
simple, non-invasive test based upon the MCM5 bio-
marker may have clinical utility in the early diagnosis of
female upper genital tract cancers.
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